| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $47,474 | 5 | 100 |
| Albertson Tina M. | Chief Medical Officer | 0 | $0 | 1 | $2,089 | $-2,089 |
| Khan Ruhi Ahmad | Chief Business Officer | 0 | $0 | 1 | $13,598 | $-13,598 |
| MCCLUNG BARBARA G | Chief Legal Officer | 0 | $0 | 1 | $13,598 | $-13,598 |
| Kelly Timothy P | Chief Technology Officer | 0 | $0 | 2 | $18,188 | $-18,188 |
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic …
Over the last 12 months, insiders at Caribou Biosciences, Inc. have bought $0 and sold $47,474 worth of Caribou Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Caribou Biosciences, Inc. have bought $47,071 and sold $172,649 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $20,400 was made by Haurwitz Rachel E. (President and CEO) on 2025‑03‑14.
| 2026-02-25 | Sale | Kelly Timothy P | Chief Technology Officer | 6,228 0.0066% | $1.93 | $12,020 | -13.08% | |
| 2026-02-24 | Sale | MCCLUNG BARBARA G | Chief Legal Officer | 6,938 0.0068% | $1.96 | $13,598 | -20.56% | |
| 2026-02-24 | Sale | Khan Ruhi Ahmad | Chief Business Officer | 6,938 0.0068% | $1.96 | $13,598 | -20.56% | |
| 2026-02-24 | Sale | Kelly Timothy P | Chief Technology Officer | 3,147 0.0031% | $1.96 | $6,168 | -20.56% | |
| 2026-02-24 | Sale | Albertson Tina M. | Chief Medical Officer | 1,066 0.001% | $1.96 | $2,089 | -20.56% | |
| 2025-03-14 | Haurwitz Rachel E. | President and CEO | 20,000 0.0217% | $1.02 | $20,400 | +70.30% | ||
| 2025-02-21 | Sale | MCCLUNG BARBARA G | Chief Legal Officer | 3,564 0.0038% | $1.35 | $4,811 | +24.43% | |
| 2025-02-21 | Sale | Kanner Steven | Chief Scientific Officer | 3,564 0.0038% | $1.35 | $4,811 | +24.43% | |
| 2025-02-21 | Sale | Khan Ruhi Ahmad | Chief Business Officer | 3,564 0.0038% | $1.35 | $4,811 | +24.43% | |
| 2025-01-29 | Ryali Sriram | Chief Financial Officer | 17,360 0.0194% | $1.42 | $24,651 | +20.15% | ||
| 2023-01-19 | Sale | Rizvi Syed Ali-aamir | Chief Medical Officer | 5,627 0.0093% | $6.31 | $35,506 | -15.90% | |
| 2022-10-06 | Sale | Fischesser Ryan | VP of Finance and Controller | 10,000 0.0162% | $10.80 | $107,958 | -43.13% | |
| 2022-08-25 | Sale | Kanner Steven | Chief Scientific Officer | 43,248 0.0707% | $11.22 | $485,221 | -40.99% | |
| 2022-01-11 | Fischesser Ryan | VP of Finance and Controller | 7,387 0.0038% | $4.00 | $29,553 | -29.34% | ||
| 2021-12-20 | Fischesser Ryan | VP of Finance and Controller | 1,136 0.0003% | $2.69 | $3,056 | -38.62% | ||
| 2021-12-07 | MCCLUNG BARBARA G | Chief Legal Officer | 6,127 0.0015% | $2.69 | $16,482 | -50.11% | ||
| 2021-10-20 | MCCLUNG BARBARA G | Chief Legal Officer | 9,219 0.0021% | $2.69 | $24,799 | -50.25% | ||
| 2021-10-12 | Kanner Steven | Chief Scientific Officer | 114,860 0.0179% | $1.92 | $220,757 | -51.66% | ||
| 2021-10-11 | Fischesser Ryan | VP of Finance and Controller | 1,746 0.0004% | $2.69 | $4,697 | -48.53% |
| MCCLUNG BARBARA G | Chief Legal Officer | 481564 0.4492% | $221,230.50 | 2 | 2 | <0.0001% |
| Haurwitz Rachel E. | President and CEO | 3369395 3.1429% | $1.55M | 1 | 0 | +70.3% |
| Kanner Steven | Chief Scientific Officer | 431556 0.4025% | $198,256.83 | 1 | 2 | <0.0001% |
| Fischesser Ryan | VP of Finance and Controller | 110366 0.1029% | $50,702.14 | 3 | 1 | <0.0001% |
| Ryali Sriram | Chief Financial Officer | 17360 0.0162% | $7,975.18 | 1 | 0 | +20.15% |
$103,288,323 | 51 | 4.78% | $56.52M | |
$24,478,755 | 37 | -34.59% | $53.59M | |
$115,646,156 | 35 | 16.45% | $54.05M | |
$47,296,259 | 27 | 18.16% | $44.4M | |
$241,165 | 22 | -16.72% | $44.02M |
| Increased Positions | 51 | +36.69% | 6M | +19.72% |
| Decreased Positions | 52 | -37.41% | 7M | -20.15% |
| New Positions | 23 | New | 1M | New |
| Sold Out Positions | 13 | Sold Out | 2M | Sold Out |
| Total Postitions | 138 | -0.72% | 33M | -0.43% |
| Vanguard Group Inc | $6,721.00 | 4.55% | 4.23M | +137,060 | +3.35% | 2025-09-30 |
| Millennium Management Llc | $5,114.00 | 3.46% | 3.22M | +2M | +107.44% | 2025-09-30 |
| Kynam Capital Management, Lp | $4,878.00 | 3.3% | 3.07M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $2,320.00 | 1.57% | 1.46M | -424,156 | -22.52% | 2025-09-30 |
| Aberdeen Group Plc | $2,208.00 | 1.49% | 1.39M | +491,326 | +54.74% | 2025-09-30 |
| Pfm Health Sciences, Lp | $2,161.00 | 1.46% | 1.36M | 0 | 0% | 2025-09-30 |
| Two Sigma Advisers, Lp | $1,952.00 | 1.32% | 1.23M | -220,400 | -15.22% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $1,924.00 | 1.3% | 1.21M | -97,045 | -7.42% | 2025-09-30 |
| Bank Of America Corp /De/ | $1,708.00 | 1.16% | 1.07M | +265,542 | +32.83% | 2025-09-30 |
| Geode Capital Management, Llc | $1,566.00 | 1.06% | 985,126 | +4,197 | +0.43% | 2025-09-30 |